Unifyl Continus

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unifyl Continus

Property Description
Active ingredient Choline Theophyllinate (Oxtriphylline)
Form Sustained-release tablet (Modified-release)
Pharmacological class Bronchodilator, Xanthine Derivative
Common use Airway obstruction support
Origin Synthetic salt form

What is Unifyl Continus and its Pharmacological Class?

Unifyl Continus is a specialized, systemic prescription medication classified as a bronchodilator belonging to the Xanthine Derivative pharmacological group. The medicine's core ingredient is Choline Theophyllinate, also identified by the International Nonproprietary Name (INN) Oxtriphylline. This compound is a synthetic salt form, specifically the choline salt of the base compound, Theophylline, and is used to provide foundational support in managing difficulties associated with restricted air flow. Within the Anatomical Therapeutic Chemical (ATC) classification system, this substance is categorized as a xanthine. Theophylline possesses a distinct action, characterized by its capability to relax smooth muscle tissue in the airways.

Composition and the Purpose of the Sustained-Release Tablet

The formulation Unifyl Continus is a single-entity product supplied as a solid oral sustained-release tablet, defining it as a type of modified-release preparation. The active ingredient, Choline Theophyllinate, is designed to release the therapeutic agent, Theophylline, slowly and consistently from the tablet's solid matrix vehicle after being taken orally. This sustained-release characteristic ensures stable concentrations of the active ingredient in the body over an extended period. These formulations are designed to maintain consistent blood levels and minimize fluctuations that can occur with immediate-release forms. This delivery method ensures that the medicine provides steady support and consistent relief.

What is the General Benefit of Taking this Medicine?

The general benefit of Unifyl Continus is its continuous ability to widen the air passages in the lungs, facilitating easier breathing and reducing general chest tightness, especially important for managing nocturnal airway restriction. This consistent bronchodilation is the medication's primary functional outcome, achieved by relaxing the smooth muscles surrounding the air passages. The resulting smooth muscle relaxant effect supports stable respiratory function, which contributes to the management of long-term obstructive airway difficulties.

Regulatory References

  1. NIH: National Library of Medicine
  2. U.S. National Library of Medicine
  3. MedlinePlus Drug Information

What side effects are possible with Unifyl Continus?

Possible side effects and safety information

The safety profile of Unifyl Continus, which delivers the active component Theophylline, is characterized by a strong dependence on its concentration in the body. The occurrence and severity of adverse reactions are documented to increase significantly at serum levels greater than 20 mu g/mL.

Official Adverse Reactions and System Groupings

Adverse effects listed in official regulatory documents predominantly involve the Nervous System and the Gastrointestinal System. Common documented effects may include headache, insomnia, restlessness, tremor, nausea, vomiting, and abdominal pain. Effects affecting the Cardiovascular System, such as tachycardia and palpitations, are also recognized.

Serious Adverse Reactions

Regulatory labeling specifies that serious adverse reactions, particularly linked to high serum concentrations, include seizures and severe cardiac arrhythmias, such as ventricular arrhythmias. These events are highlighted as clinically significant and may be associated with risk of long-term harm.

Population-Specific Safety Considerations

The medicine's regulatory profile notes that clearance is substantially reduced in several specific populations, increasing the potential for toxicity. These groups include older adults (over 60 years), patients with hepatic impairment (e.g., cirrhosis), and individuals with Congestive Heart Failure (CHF). Additionally, the drug should be used with particular caution in patients with pre-existing conditions such as active peptic ulcer disease or seizure disorders, as the medicine may aggravate these conditions. Safety notes also advise that changes in physiological status, such as the onset of a fever or smoking cessation, can reduce clearance and alter the risk profile.

Overdose and Emergency Response

Overdose Manifestations and Scope

Overdose of Unifyl Continus (Oxtriphylline/Theophylline) is defined by a range of signs reflecting central nervous system (CNS) and cardiac excitability. Initial manifestations commonly documented in regulatory texts include gastrointestinal distress such as nausea, vomiting, and epigastric pain, alongside CNS symptoms like headache, restlessness, and fine tremor. Cardiovascular effects include tachycardia and palpitations. Due to the sustained-release formulation, the onset of severe toxicity and peak serum levels may be delayed, requiring vigilance. Children and the elderly are noted in official labeling as being more susceptible to severe manifestations.

Life-Threatening Outcomes and Emergency Actions

The official profile classifies overdose as having the potential for severe and life-threatening outcomes. The most serious documented manifestations are seizures, which may progress to status epilepticus, and severe ventricular arrhythmias, including cardiac arrest. Significant metabolic disturbances, such as hypokalemia, are also recognized. Regulatory guidance mandates that patients seek immediate medical attention or contact emergency services upon the suspicion of overdose or the observation of severe symptoms. Management is symptomatic and supportive, focusing on stabilization and enhanced elimination; no specific antidote is known to reverse the toxic effects of theophylline.

Therapeutic Uses of Unifyl Continus

As a foundational therapy for chronic respiratory conditions, Unifyl Continus (Oxtriphylline) is commonly used to help manage symptoms related to long-term lung diseases. This medication is applied across domains where additional symptomatic support is needed, involving conditions like chronic asthma, emphysema, and Chronic Obstructive Pulmonary Disease (COPD).

This medication is generally used to help with conditions characterized by periods of episodic or fluctuating manifestations, playing a role in managing symptoms that create noticeable physiological strain on the respiratory system. The therapy is primarily applied in addressing symptom clusters related to physical discomfort and heightened physiological activity, such as wheezing, uncomfortable chest tightness, and shortness of breath.

“The sustained-release profile is considered relevant for supporting the management of symptoms throughout the day and night.”

Given the nature of this sustained-release support, this therapy is considered relevant for supporting patients during episodes of heightened discomfort by contributing to easing the overall symptom load, and may help improve day-to-day comfort during symptomatic periods, including those at night.

Quick Fact: Relevant for Easing Symptoms Related to Breathing Difficulty

Regulatory References

  1. NIH MedlinePlus overview on Theophylline

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Unifyl Continus

Regulatory authorities define specific populations who can and cannot use Unifyl Continus (Theophylline) based on contraindications and the drug's metabolism.

Absolute Contraindications

Use is strictly prohibited in patients with a known history of hypersensitivity to theophylline or any other xanthine derivative.

Restricted or Conditional Use Populations

Population Group Eligibility Status (Regulatory Basis)
Infants/Neonates Clearance is highly deficient and variable; use is contraindicated by some authorities for children under 6 months of age.
Older Adults (≥60 years) Clearance is decreased; use requires caution and monitoring due to increased toxicity risk.
Hepatic Impairment Restricted use; clearance is significantly decreased (e.g., in cirrhosis), requiring frequent monitoring and potential dose reduction.
Pregnancy US FDA Pregnancy Category C; use is permissible only if the potential benefit justifies the potential risk to the fetus.
Comorbidities Caution required for patients with active peptic ulcer disease, seizure disorders, and cardiac arrhythmias due to the risk of condition exacerbation or altered clearance (e.g., in Congestive Heart Failure).

Eligibility is primarily determined by conditions that significantly impact the body's ability to clear the drug or conditions that are listed as having a risk of exacerbation.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for this medicine is defined by substances that affect its concentration in the body or those that share similar physiological effects.

Exposure-Modifying Substances

Co-administration with other medicines may significantly alter the level of this drug in the bloodstream. Medicines that inhibit metabolic processes, such as certain antibiotics (e.g., ciprofloxacin, erythromycin) or H2-receptor antagonists (e.g., cimetidine), can lead to an increase in systemic levels. Conversely, medicines that speed up metabolic clearance, such as certain anticonvulsants (e.g., phenytoin) or the use of tobacco products, can decrease systemic levels.

Pharmacodynamic Interactions

Additive effects are noted when this product is combined with other substances that possess similar actions. For example, co-administration with other xanthine-containing products or certain stimulants may heighten central nervous system effects. The combination with certain agents, such as general anesthetics (e.g., ketamine) or specific antidepressants (e.g., bupropion), is documented to lower the convulsive threshold. Additionally, this product may inhibit the effects of adenosine and dipyridamole.

Practical Considerations

Consistent brand use is recommended to maintain stable drug absorption. Changes in patient status, such as the onset of a sustained fever or the cessation of tobacco use, may require close monitoring due to their potential to alter the drug's clearance.

Mechanism of Action

Enzyme Inhibition and Airway Smooth Muscle Relaxation

The active component, Theophylline, exerts its action through the inhibition of Phosphodiesterase (PDE) enzymes, particularly those found in airway smooth muscle cells. This inhibition raises intracellular levels of the messenger cyclic adenosine monophosphate ( cAMP), initiating a molecular cascade that results in the relaxation of airway smooth muscle. This physiological change results in the widening of the air passages.


Modulation of Cellular Signaling and Receptor Antagonism

The compound acts as a non-selective antagonist of Adenosine Receptors and works to restore the function of Histone Deacetylase 2 (HDAC2), a nuclear enzyme essential for gene regulation. These actions dampen the release of constrictive cellular mediators and modulate the transcription of inflammatory genes, leading to the attenuation of cellular signaling that promotes contraction or inflammation.


Enhancement of Central and Diaphragmatic Respiratory Function

The mechanism also involves direct stimulation of the medullary respiratory center and an enhancement of diaphragm contractility. This central and peripheral neural-muscular activity increases the ventilatory drive and the functional capacity of the diaphragm muscle, thereby driving an increased ventilatory response and enhanced contractility of respiratory muscles.

Dosage and Administration Information

How to use Unifyl Continus: Official Administration Guidelines

This section outlines the administration requirements for Unifyl Continus (Oxtriphylline sustained-release tablet), focusing on proper use.


Administration Scope

Instruction Detail
Route of Administration Oral administration only.
Dosing Schedule (Adults) Individualized based on monitoring. Typical daily maintenance is up to 600 mg in adults over 45 kg, often starting lower and adjusting upward.
Timing in Relation to Meals May be taken with or without food.
Age-Group Rules Lower maximum doses, such as 400 mg per day, may be applied to older adults (over 60 years) or those with impaired liver function.
Missed-Dose Rules If a dose is missed but remembered within 4 hours of the scheduled time, it can be taken immediately, with the next dose at the normal time.

Special Procedural Conditions

The sustained-release nature of the tablet dictates specific handling requirements to ensure controlled delivery:

  • The tablet must be swallowed whole and should not be broken, crushed, or chewed, as doing so compromises the prolonged-release mechanism.
  • It should be taken at the same time each day (e.g., every 12 hours) to maintain consistent drug levels in the bloodstream.
  • Dose adjustments must be made slowly, with intervals of no less than 3 days between changes, which allows time for the body's concentration of the active ingredient to stabilize.
  • The determination of the correct dose is guided by measuring serum theophylline concentrations.

Connection to the Overall Use Protocol

These instructions standardize the method, frequency, and timing of administration to maximize the stability of the sustained-release profile. Procedural steps, including minimum titration intervals and monitoring, define the structure for its long-term, chronic use.

Recent Clinical Evidence

Unifyl Continus: Recent Clinical Evidence

Evidence for Use in Chronic Asthma and Nocturnal Symptoms

The medicine was evaluated in adults and children with chronic asthma, focusing on conditions characterized by fluctuating or episodic manifestations. Studies primarily used Randomized Controlled Trials (RCTs) to monitor airway function (FEV1) and patient-reported outcomes describing perceived discomfort. Specific attention was studied for nocturnal asthma, as the sustained-release nature of the compound is relevant in trials assessing short-term or episodic symptom patterns throughout the night. Data show patterns related to measured changes in pulmonary function and symptom scores in the observed populations. Research notes that follow-up durations were limited, and some studies reported mixed findings regarding objective sleep quality.

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Unifyl Continus was evaluated in patients with Chronic Obstructive Pulmonary Disease (COPD) through systematic reviews and comparative trials. The primary goals of this research were studied for outcomes related to physical discomfort, specifically measuring changes in lung function and patient-reported symptoms. Research has also explored whether the medicine may be associated with changes in the frequency of acute, disruptive episodes. A key limitation is that comparative evidence is lacking against many of the newest available bronchodilators, and findings related to potential outcomes linked to inflammatory or irritative states were often mixed.

Research on the Sustained-Release Formulation and Long-Term Follow-up

Specialized Pharmacokinetic (PK) Studies and bioequivalence trials were evaluated to confirm the tablet maintains stable drug concentrations within the blood plasma over a 24-hour period. This research is critical as the active compound has a narrow therapeutic window. While evidence includes studies of children and older adults, long-term effects are not fully established regarding consistent use over many years. Follow-up durations were limited in core efficacy trials, meaning that long-term outcomes are not well characterized, and the research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Unifyl Continus (FAQ)


Q: What is the main reason a doctor would prescribe Unifyl Continus?

Official prescribing information indicates the medicine is used to help manage the symptoms and reversible airflow obstruction associated with chronic conditions, such as asthma, chronic bronchitis, and emphysema (which is a form of COPD). It is primarily used to provide long-term bronchodilation, which means widening the air passages in the lungs.


Q: How quickly should I expect to see an effect from Unifyl Continus?

Because Unifyl Continus is a sustained-release formulation, it is designed to work slowly and consistently over time, rather than providing an immediate effect. Studies show the active ingredient typically reaches its peak concentration in the blood around 5 to 8 hours after taking the tablet. This delayed peak helps maintain steady levels for ongoing symptom management.


Q: What happens if I miss a dose of Unifyl Continus?

The official administration guidelines state that if a dose is remembered within 4 hours of the scheduled time, it can be taken immediately, with the next dose at the normal scheduled time. The regulatory text specifies that this allowance is up to 4 hours, but does not provide instructions for a longer elapsed time.


Q: Does Unifyl Continus interact with common over-the-counter pain relievers?

Interactions between the active ingredient, Theophylline, and common pain relievers are documented in medical literature. For example, Theophylline is noted to potentially interact with Acetaminophen, which may increase the risk of liver effects associated with Acetaminophen. Regulatory agencies advise that healthcare providers should be informed of all over-the-counter medicines being used for a complete review.


Q: Can I take Unifyl Continus with multivitamins or supplements?

Healthcare providers are advised in official documentation to be informed about all medicines, vitamins, and supplements being used. Certain supplements, such as the herbal remedy St. John's wort, are noted for potentially speeding up the body's clearance of the active ingredient, which could lead to lower levels in the body.


Q: Does Unifyl Continus interact with alcohol?

Yes, regulatory documents note that alcohol can affect how the body processes the active ingredient, Theophylline. Specifically, consuming a large single dose of alcohol may decrease the rate at which the body clears the medicine, potentially leading to higher drug levels. For this reason, regulatory information often notes that caution is needed with alcohol consumption.


Q: How long does Unifyl Continus stay in my system after I stop taking it?

The time it takes for the medicine to be cleared from the body is based on its half-life, which is the time required for half the dose to be eliminated. The mean half-life associated with the active ingredient in healthy, non-smoking adults is approximately 7 to 8 hours. The complete clearance of the medicine from the body is based on this half-life and typically takes several cycles.


Q: Is Unifyl Continus meant to be taken with or without food?

Official administration instructions state that the medicine may be taken either with food or without food. However, official regulatory instructions emphasize that consistency is necessary; each dose should be taken the same way (always with food or always without) to maintain stable drug levels.


Q: Does Unifyl Continus treat symptoms or a specific condition?

The active component in Unifyl Continus is classified as a bronchodilator. This means its primary function is to relieve the symptoms associated with airflow obstruction and chronic lung diseases, such as wheezing and shortness of breath, rather than curing the underlying condition.


Q: Is Unifyl Continus considered a long-term or short-term medication?

Regulatory documentation indicates the medicine is prescribed for the management of chronic conditions, such as asthma and COPD. This structure of use supports a treatment plan for long-term management. The long-term nature of its use requires regular assessment.


Q: Is Unifyl Continus the same as other similar-sounding medicines?

Unifyl Continus contains the active component Choline Theophyllinate (Oxtriphylline), which is a salt form of Theophylline, a medication belonging to the Xanthine Derivative drug class. While the base compound, Theophylline, is used in many other medicines, the specific formulation and salt in Unifyl Continus may differ from others.


Q: Is it normal to feel a bit dizzy when starting Unifyl Continus?

The official safety profile for the active ingredient lists central nervous system (CNS) effects as potential adverse reactions. Documented CNS effects may include dizziness or feeling lightheaded, especially if the levels of the medicine in the blood become higher than the recommended range.


Q: What foods or drinks should be avoided while taking Unifyl Continus?

Official information notes that caution is warranted regarding the consumption of excessive amounts of foods and beverages that contain caffeine, such as coffee, tea, cola, and chocolate. This is because caffeine is also a xanthine compound and can potentially add to the central nervous system stimulating effects of the medicine.


Q: Is there a list of ingredients in Unifyl Continus that I should know about?

Regulatory documents list both the active component (Oxtriphylline/Theophylline) and the inactive ingredients, also known as excipients, in the tablet. These inactive ingredients typically include substances necessary for the tablet structure and sustained-release property, such as hypromellose and magnesium stearate.


Q: What kind of studies support the use of Unifyl Continus?

The use of this medicine is supported by evidence from various types of studies. These include Randomized Controlled Trials (RCTs) to assess how effectively the medicine improves pulmonary function, as well as Pharmacokinetic (PK) studies to confirm that the sustained-release tablet maintains stable drug concentrations in the body over time.


Q: Has Unifyl Continus been approved in countries outside of the US?

Yes, regulatory authorities in various regions, including European countries, have approved and published documentation for the active ingredient, Theophylline, under various brand names and formulations, indicating its use outside of the United States.


Q: Are there any specific lifestyle changes that are recommended when using Unifyl Continus?

Regulatory warnings highlight that smoking tobacco products increases the body's rate of clearing the medicine, which can affect drug levels. Therefore, changes in smoking habits, such as quitting, may require close monitoring. Caution related to alcohol and excessive caffeine intake is also noted in regulatory information.


Q: Can Unifyl Continus affect my ability to drive or operate machinery?

The medicine can cause adverse reactions that affect the central nervous system, such as dizziness, insomnia, and tremor. Official information indicates that effects on alertness may impair the ability to drive or operate machinery.


Q: How is Unifyl Continus typically packaged or sold?

According to regulatory labeling, the extended-release tablets are generally packaged in bottles containing various quantities. The typical count depends on the strength and the dispensing volume, with common sizes ranging from 30 up to 500 tablets.


Q: What is the maximum duration people usually take Unifyl Continus for?

The medicine is indicated for the treatment of chronic lung conditions, which supports its use for an extended period. The duration of use is determined on an individual basis, guided by the patient's response and professional monitoring.


Q: Are there any known interactions between Unifyl Continus and herbal remedies?

Regulatory documents state that healthcare providers should be informed about the use of any herbal remedies or supplements. Specific herbal products, such as Ephedra and St. John's wort, are noted for potentially altering the blood concentration of the active ingredient or increasing the risk of adverse effects.


Q: If Unifyl Continus is prescribed for one condition, can it help with another?

Unifyl Continus is officially indicated only for the treatment of symptoms associated with chronic asthma and other specific chronic lung diseases. The use of the medicine for any other condition is outside of the official prescribing information reviewed and approved by regulatory bodies.


Q: Can Unifyl Continus cause changes in mood or personality?

The central nervous system (CNS) adverse reactions listed in regulatory documents include nervousness, irritability, and restlessness. At very high concentrations, confusion or disorientation may occur. These documented effects are related to changes in behavior or mood.


Q: Is Unifyl Continus available in a generic version?

Yes, the active ingredient in Unifyl Continus, Theophylline, is widely available in generic extended-release tablet forms offered by various pharmaceutical manufacturers. Generic versions must meet the same quality and effectiveness standards as the brand-name product.


Q: Are there different strengths of Unifyl Continus available?

Official drug labels indicate that Theophylline extended-release tablets are typically available in several different strengths. Common strengths include 100 mg, 200 mg, 300 mg, and 450 mg, allowing for dose individualization based on monitoring.


Q: Can Unifyl Continus be used during breastfeeding?

Official information indicates that the active ingredient passes into human breast milk. While serious adverse effects in nursing infants are uncommon, potential for mild toxicity in the infant, such as irritability or difficulty sleeping, is noted. The potential use during breastfeeding is a matter for professional assessment.


Q: Does Unifyl Continus have any known risk of dependency or misuse?

The medicine is classified as a prescription-only drug but is not listed as a controlled substance by regulatory bodies. This indicates that Unifyl Continus is not associated with the known risks of dependency or misuse that are linked to medicines classified under the Controlled Substances Act, such as opioids or benzodiazepines.

How should Unifyl Continus be stored and disposed of?

How to Store and Dispose of Unifyl Continus

Storage of Unifyl Continus (Theophylline prolonged-release tablets) must follow specific regulatory requirements to maintain product integrity.

Storage Conditions

The medicine requires storage at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C. The tablets must be kept in a tightly closed container and stored in a dry place, protected from moisture and excessive heat. For safety, the product must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be disposed of in accordance with local regulations, preferably utilizing a drug take-back program. The product must not be flushed down the toilet. If no program is available, the tablets can be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unifyl Continus found in:

A-Z Index: